KRAS and lung cancer: In addition, the deletion of PCDH7 has been shown to increase the sensitivity of mutant lung cancer cells with KRAS mutation to MEK and ERK inhibitors, thus the treatment of PCDH7 may have a synergistic effect with EGFR or MAPK inhibitors17.